Physician's Weekly3d
Using Targeted Interventions to Elevate QOL & Symptom Control in Plaque Psoriasis
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Medscape8d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Dermatology Advisor3d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Healio20d
Oral TYK2 inhibitor has ‘outstanding efficiency’ in plaque psoriasis
Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...
Healio26d
New 5-year data showcase Sotyktu’s long-term efficacy, safety for plaque psoriasis
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.